Log in

Eagle Pharmaceuticals Stock Price, News & Analysis (NASDAQ:EGRX)

$61.71
-0.80 (-1.28 %)
(As of 10/20/2019 04:00 PM ET)
Today's Range
$61.03
Now: $61.71
$62.93
50-Day Range
$54.45
MA: $57.84
$62.67
52-Week Range
$36.03
Now: $61.71
$62.98
Volume79,117 shs
Average Volume170,271 shs
Market Capitalization$843.58 million
P/E Ratio29.53
Dividend YieldN/A
Beta1.41
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EGRX
CUSIPN/A
Phone201-326-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$213.31 million
Cash Flow$2.38 per share
Book Value$10.78 per share

Profitability

Net Income$31.90 million

Miscellaneous

Employees96
Market Cap$843.58 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.


Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) released its quarterly earnings data on Thursday, August, 8th. The specialty pharmaceutical company reported $0.48 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.31 by $0.17. The specialty pharmaceutical company had revenue of $56.70 million for the quarter, compared to the consensus estimate of $53.61 million. Eagle Pharmaceuticals had a return on equity of 24.10% and a net margin of 19.79%. The company's revenue was down 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.99 EPS. View Eagle Pharmaceuticals' Earnings History.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Eagle Pharmaceuticals.

What price target have analysts set for EGRX?

4 equities research analysts have issued 1-year price objectives for Eagle Pharmaceuticals' shares. Their forecasts range from $50.00 to $66.00. On average, they anticipate Eagle Pharmaceuticals' stock price to reach $57.00 in the next twelve months. This suggests that the stock has a possible downside of 7.6%. View Analyst Price Targets for Eagle Pharmaceuticals.

What is the consensus analysts' recommendation for Eagle Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Eagle Pharmaceuticals.

What are Wall Street analysts saying about Eagle Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (10/17/2019)
  • 2. Cantor Fitzgerald analysts commented, ". Post 1Q19, we are reiterating our Neutral rating and our 12- month price target on EGRX shares of $58. Pipeline setbacks in 2018 have created an overhang on the visibility of near term growth drivers for EGRX, which keeps us on the sidelines for now. Given the current visibility, we believe EGRX stock remains fairly valued at current levels. That said, EGRX’s current business continues to perform well and the company is advancing Ryanodex for nerve agent exposure and acute radiation syndrome, both of which we believe have the potential to get into the strategic national stockpile, if successful." (5/7/2019)

Has Eagle Pharmaceuticals been receiving favorable news coverage?

Press coverage about EGRX stock has been trending somewhat positive on Sunday, InfoTrie reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Eagle Pharmaceuticals earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Eagle Pharmaceuticals.

Are investors shorting Eagle Pharmaceuticals?

Eagle Pharmaceuticals saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 1,730,000 shares, a drop of 9.9% from the August 30th total of 1,920,000 shares. Based on an average daily volume of 150,800 shares, the short-interest ratio is currently 11.5 days. Approximately 13.2% of the shares of the stock are short sold. View Eagle Pharmaceuticals' Current Options Chain.

Who are some of Eagle Pharmaceuticals' key competitors?

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Exelixis (EXEL), Gilead Sciences (GILD), Teekay Tankers (TNK), Celgene (CELG), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT), Synergy Pharmaceuticals (SGYP), Radius Health (RDUS), bluebird bio (BLUE) and Clovis Oncology (CLVS).

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the folowing people:
  • Mr. Scott L. Tarriff, CEO & Director (Age 59)
  • Mr. David M. Pernock, Pres & Chief Operating Officer (Age 66)
  • Mr. Pete A. Meyers, Chief Financial Officer (Age 49)
  • Dr. Adrian Hepner, Exec. VP & Chief Medical Officer (Age 58)
  • Mr. Daniel O'Connor, Exec. VP of Biologics & Corp. Devel. (Age 39)

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Smith Graham & Co. Investment Advisors LP (1.13%), Scout Investments Inc. (0.67%), Envestnet Asset Management Inc. (0.08%), State of Alaska Department of Revenue (0.06%), Robeco Institutional Asset Management B.V. (0.05%) and Pacer Advisors Inc. (0.05%). Company insiders that own Eagle Pharmaceuticals stock include Douglas L Braunstein, Hudson Executive Capital Lp, Sander A Flaum and Scott Tarriff. View Institutional Ownership Trends for Eagle Pharmaceuticals.

Which institutional investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc.. Company insiders that have sold Eagle Pharmaceuticals company stock in the last year include Douglas L Braunstein, Hudson Executive Capital Lp and Scott Tarriff. View Insider Buying and Selling for Eagle Pharmaceuticals.

Which institutional investors are buying Eagle Pharmaceuticals stock?

EGRX stock was purchased by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., State of Alaska Department of Revenue, Envestnet Asset Management Inc., Pacer Advisors Inc. and Smith Graham & Co. Investment Advisors LP. View Insider Buying and Selling for Eagle Pharmaceuticals.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $61.71.

How big of a company is Eagle Pharmaceuticals?

Eagle Pharmaceuticals has a market capitalization of $843.58 million and generates $213.31 million in revenue each year. The specialty pharmaceutical company earns $31.90 million in net income (profit) each year or $2.09 on an earnings per share basis. Eagle Pharmaceuticals employs 96 workers across the globe.View Additional Information About Eagle Pharmaceuticals.

What is Eagle Pharmaceuticals' official website?

The official website for Eagle Pharmaceuticals is http://www.eagleus.com/.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]


MarketBeat Community Rating for Eagle Pharmaceuticals (NASDAQ EGRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  372 (Vote Outperform)
Underperform Votes:  246 (Vote Underperform)
Total Votes:  618
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe EGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel